A single but durable stable disease sends the microcap's stock up 730%.
ApexOnco Front Page
Recent articles
14 July 2025
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
30 June 2025
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
30 June 2025
Regeneron is facing two FDA decisions for its T-cell engagers.
26 June 2025
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
26 June 2025
The company reckons its immunotherapy could improve on Keytruda.